Royalty Pharma may offer $6.6 billion bid for Elan

DUBLIN (Reuters) - U.S. investment firm Royalty Pharma has made a $6.6 billion approach to Irish drugmaker Elan, targeting royalty rights for multiple sclerosis treatment Tysabri worth hundreds of millions of dollars annually.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news